相关实验视频

Updated: Jul 5, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

在青少年异常性关节炎中选择和转换生物药物

Seher Şener¹, Özge Başaran¹, Ezgi Deniz Batu¹

¹Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University, Ankara, Türkiye.

The Turkish journal of pediatrics

|January 11, 2024

概括

青少年异常性关节炎 (JIA) 的生物药物选择因亚型而异,乙太经常用于与肠炎相关的关节炎和橄关节/多关节性JIA. 切换生物药物是常见的,通常是由于使用问题或不充分的反应.

科学领域:

类风湿病学类风湿病学
儿科风湿病学儿科风湿病学
药理学药理学是指药理学的学科.

背景情况:

青少年异常性关节炎 (JIA) 是一种异质的自身免疫性疾病,需要不同的治疗策略.
生物药物代表了管理中度至重度JIA在各种亚型的基石.
了解生物药物利用模式对于优化患者治疗结果至关重要.

研究的目的:

分析在患有不同类型青少年异常性关节炎的患者中选择和顺序使用生物疗法.
为了确定在JIA患者中切换生物药物的常见原因.
评估生物治疗的安全性和有效性概况在现实世界的JIA队列中.

主要方法:

在2004年1月至2022年7月期间,对294名青少年异形性关节炎患者进行了回顾性分析,这些患者在2004年1月至2022年7月期间接受了生物治疗.
根据JIA亚型对患者进行分类:全身性,小关节性,多关节性,肠炎相关性关节炎 (ERA) 和牛皮性关节炎 (PsA).
第一线,第二线和第三线生物药物选择的文件,以及治疗修改的原因.

主要成果:

埃坦尼塞普特是最常见的第一线生物药物,用于ERA,小关节性和多关节性JIA,而阿纳金拉是系统性JIA的首选药物,而阿达利穆马布用于PSA.
38.8%的患者需要二线和9.9%的患者需要三线生物治疗.
转换的原因包括每日注射的困难 (全身性JIA) 和不充分的反应 (非全身性JIA);副作用不常见 (2.4%).

结论:

在JIA中选择生物药物取决于亚型,对特定药物的偏好已经确立.
治疗修改是常见的,由患者特异性因素驱动,如给药方便和治疗疗效.
观察到的治疗策略产生了良好的反应,但需要更大的研究来证实这些发现.

关键词:

这就是Adalimumab.亚纳金拉的孩子们乙醇接收剂乙醇接收剂青少年异常性关节炎 (Idiopathic Arthritis) 是一种疾病.

更多相关视频

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Factors Affecting Drug Response: Overview

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...